당뇨황반부종에서 0.1% 브롬페낙 점안액의 효과
The Effect of a 0.1% Bromfenac Solution on Diabetic Macular Edema
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
목적: 당뇨황반부종에서 0.1% 브롬페낙 점안액의 치료 효과를 알아보고자 하였다. 대상과 방법: 유리체내 베바시주맙 주사 후에도 지속되는 당뇨황반부종에 1일 2회 0.1% 브롬페낙 점안액 치료를 받은 14명(14안)의 의무기록을 후향적으로 분석하였다. 브롬페낙 치료 전, 치료 후 1개월, 2개월, 3개월의 중심황반두께와 최대교정시력의 변화를 관찰하였다. 각막독성 등의 이상 반응 발생 여부도 확인하였다. 결과: 브롬페낙 치료 전 평균 logarithm of the minimum angle of resolution (logMAR) 시력은 0.40 ± 0.29였고, 중심황반두께는 337.0 ± 97.3 μm였다. 브롬페낙 치료 후 평균 시력은 1개월 0.39 ± 0.29, 2개월 0.38 ± 0.24, 3개월 0.34 ± 0.21로 통계적으로 유의한 호전을 보이지는 않았다(p=0.93, p=0.62, p=0.36). 평균 중심황반두께는 치료 후 1개월 331.4 ± 67.9 μm, 2개월 311.7 ± 89.1 μm, 3개월 282.9 ± 76.7 μm로 브롬페낙 치료 후 3개월째에 통계적으로 유의한 호전을 보였다(p=0.47, p=0.08, p=0.04). 연구 기간 동안브롬페낙 점안액으로 인해 부작용을 호소하거나 약제 사용을 중단한 사례는 없었다. 결론: 0.1% 브롬페낙 점안액은 당뇨황반부종에서 황반부종을 감소시키는 효과가 있었다.
Abstract
Purpose: The short-term outcomes of patients with diabetic macular edema (DME) treated with 0.1% Bromfenac eyedrops were evaluated. Methods: We included 14 eyes of 14 patients diagnosed with persistent macular edema after intravitreal bevacizumab injection to treat DME. Bromfenac sodium hydrate 0.9 mg/mL eyedrops were administered to the affected eye twice daily for 3 months. The best corrected visual acuity (BVCA) and central macular thickness (CMT) were measured before treatment and at 1, 2, and 3 months after treatment. We noted no adverse drug reaction such as corneal toxicity. Results: After 2 months of intravitreal bevacizumab and before Bromfenac eyedrops treatment, the logarithm of the minimal angle of resolution (logMAR) BCVA and the CMT were 0.40 ± 0.29 and 337 ± 97.3 μm, respectively. The logMAR BCVA decreased from 0.40 ± 0.29 to 0.39 ± 0.29 after 1 month, to 0.38 ± 0.24 after 2 months, and to 0.34 ± 0.21 after 3 months of Bromfenac treatment, but statistical significance was not attained (p = 0.93, p = 0.62, and p = 0.36 respectively). The CMT improved significantly from 337 ± 97.3 μm to 331 ± 67.9 μm after 1 month, 311 ± 89.1 μm after 2 months, and 282.9 ± 76.7 μm after 3 months (p = 0.47, p = 0.08, and p = 0.04, respectively). Treatment was well-tolerated; we noted no topical or systemic side-effect. Conclusions: Topical bromfenac may play a useful role in terms of reducing DME.
참고문헌 (28)
- Acan D, "The prevalence and systemic risk factors of diabetic macular edema : a cross-sectional study from Turkey", BMC Ophthalmol, 18, pp.91~ (2018)
- Ferris FL 3rd, "Macular edema. A complication of diabetic retinopathy", Surv Ophthalmol, 28(Suppl), pp.452~461 (1984)
- Schatz H, "Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular edema", Arch Ophthalmol, 109, pp.1549~1551 (1991)
- Fong DS, "Subretinal fibrosis in diabetic macular edema. ETDRS report 23. Early Treatment Diabetic Retinopathy Study Research Group", Arch Ophthalmol, 115, pp.873~877 (1997)
- Falavarjani KG, "Adverse events and complications associated with intravitreal injection of anti-VEGF agents : a review of literature", Eye(Lond), 27, pp.787~794 (2013)
- Funatsu H, "Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema", Ophthalmology, 110, pp.1690~1696 (2003)
- Noma H, "Vitreous levels of interleukin-6and vascular endothelial growth factor in macular edema with central retinal vein occlusion", Ophthalmology, 116, pp.87~93 (2009)
- Jones J, "Ophthalmic utility of topical bromfenac, a twice-daily nonsteroidal anti-inflammatory agent", Expert Opin Pharmacother, 10, pp.2379~2385 (2009)
- Russo A, "Topical nonsteroidal anti-inflammatory drugs for macular edema", Mediators Inflamm, 2013, pp.476525~ (2013)
- Schoenberger SD, "Nonsteroidal anti-inflammatory drugs for retinal disease", Int J Inflam, 2013, pp.281981~ (2013)
- Shimura M, "Topical bromfenac reduces the frequency of intravitreal bevacizumab in patients with branch retinal vein occlusion", Br J Ophthalmol, 99, pp.215~219 (2015)
- Gomi F, "Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration", Retina, 32, pp.1804~1810 (2012)
- Pinna A, "Bromfenac eyedrops in the treatment of diabetic macular edema : a pilot study", Eur J Ophthalmol, 27, pp.326~330 (2017)
- Congdon NG, "Corneal complications associated with topical ophthalmic use of nonsteroidal antiinflammatory drugs", J Cataract Refract Surg, 27, pp.622~631 (2001)
- Gardner TW, "Diabetic retinopathy:more than meets the eye", Surv Ophthalmol, 47(Suppl 2), pp.S253~S262 (2002)
- Miyake K, "Prostaglandins and cystoid macular edema", Surv Ophthalmol, 47(Suppl 1), pp.S203~S218 (2002)
- Joussen AM, "Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression", FASEB J, 16, pp.438~440 (2002)
- Ayalasomayajula SP, "Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model", Eur J Pharmacol, 458, pp.283~289 (2003)
- Kern TS, "Topical administration of nepafenac inhibits diabetes-induced retinal microvascular disease and underlying abnormalities of retinal metabolism and physiology", Diabetes, 56, pp.373~379 (2007)
- Mahmut Kaya, "Effectiveness of Intravitreal Ranibizumab for Diabetic Macular Edema with Serous Retinal Detachment", Korean Journal of Ophthalmology, 32(4), pp.296~302 (2018), 대한안과학회[DOI]
- Kim BY, "Optical coherence tomographic patterns of diabetic macular edema", Am J Ophthalmol, 142, pp.405~412 (2006)
- Browning DJ, "The relationship of macular thickness to clinically graded diabetic retinopathy severity in eyes without clinically detected diabetic macular edema", Ophthalmology, 115, pp.533~539.e2 (2008)
- Sharief L, "Prospective study of morphologic and functional parameter changes post intravitreal therapy for macular edema", Graefes Arch Clin Exp Ophthalmol, 258, pp.1941~1947 (2020)
- Maheshwary AS, "The association between percent disruption of the photoreceptor inner segment", outer segment and visual acuity in diabetic macular edema, 2010, pp.150, 63~67.e1
- Fursova AZ, "Clinical associations between photoreceptor status and visual outcomes in diabetic macular edema", Vestn Oftalmol, 133, pp.11~18 (2017)
- Zweifel SA, "Retrospective review of the efficacy of topical bromfenac (0.09%) as an adjunctive therapy for patients with neovascular age-related macular degeneration", Retina, 29, pp.1527~1531 (2009)
- Flaxel C, "Prospective randomized controlled trial of combination ranibizumab(Lucentis)and bromfenac(Xibrom)for neovascular age-related macular degeneration : a pilot study", Retina, 32, pp.417~423 (2012)
- Li S, "Combinatorial treatment with topical NSAIDs and anti-VEGF for age-related macular degeneration, a meta-analysis", PLoS One, 12, pp.e0184998~ (2017)